The study, called COVACTA, is the first randomized, double-blind, placebo-controlled phase III trial of the drug. The examination of 450 patients at 67 sites in the United States was conducted through the company in collaboration with the Advanced Biomedical Research and Development Authority (BARDA), a firm of the U.S. Department of Health and Human Services.
“People around the world are expecting other effective remedy functions for COVID-19 and we are disappointed that COVACTA has not shown any advantage for patients in clinical condition or mortality until the fourth week. We will continue to generate evidence to provide more full understanding of Actemra/RoActemra in COVID-19-associated pneumonia,” said Levi Garraway, Roche’s director of global product development, in a statement.
However, the company said it remained committed to continuing the Actemra clinical trial program on covid-19 to further explore the use of the drug in other remedy environments, adding a mixture with an antiviral.
The intravenous drug is also sold in India through the authorized company Cipla Ltd with the Actemra logo. Cipla has set the value of the medicinal product at 40,500 ₹ per 400 mg vial.
Tocilizumab has been included in the clinical control protocol of the Indian Ministry of Health for covid-19 as a noncondlic drug, a term referring to the use of a drug in an emergency for the treatment of an unconfirmed medical condition or disease.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.